Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.

Topic Addiction
Compound Psilocybin
Country United States of America
Visit trial
Status Not yet recruiting
Results Published
Start date 15 January 2022
End date 31 December 2023
Chance of happening 88%
Phase Phase I Phase II
Design Open
Type Interventional
Generation First
Participants 30
Sex All
Age 18- 99
Therapy No

Trial Details

The trial will take place with individuals admitted to a residential rehabilitation treatment program. The treatment protocol will consist of 4 preparatory therapy visits, 2 psilocybin sessions (25-30mg), and 8 total integration therapy visits. Primary aims assess acceptability, feasibility, and safety with a primary endpoint at the conclusion of the study intervention. An additional aim assesses preliminary efficacy for methamphetamine use disorder and overall functioning at follow-up assessments 60 and 180 days after discharge from the residential treatment program.

NCT Number NCT04982796

Sponsors & Collaborators

Oregon Health & Science University
Psychedelic research is underway at the Oregon Health and Science University. It is likely more research will emerge given the state recently legalized psilocybin.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.